Allergy/Imm Medical News about imipenem

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Novel therapies for children with severe asthma

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Cross-reactivity and tolerability of imipenem in patients with delayed-type, cell-mediated hypersensitivity to -lactams
Allergy, 10/16/09

Schiavino D et al. – The rate of cross–reactivity between imipenem–cilastatin and other beta–lactams was 5.5%. This result is different from previous findings and this may be explained by the fact that authors investigated patients with cell–mediated allergy to beta–lactams. Patients with cell–mediated allergy to beta–lactams should undergo patch tests and a tolerance challenge test before treatment with imipenem–cilastatin.

<< Previous
Long-term follow-up of the original interferon-beta1b trial in...

Next >>
Cost-effectiveness of clean air administered to the breathing...

Epidemiology and Impact of Imipenem Resistance in Acinetobacter baumannii
Infection Control and Hospital Epidemiology, 10/28/09 Relevance Score: 83%

Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation
Current Medical Research and Opinion, 11/13/09 Relevance Score: 80%

Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates
American Journal of Infection Control, 11/12/09 Relevance Score: 80%

Recurrent cellulitis following buttock augmentation
The Clinical Advisor, 11/09/09 Relevance Score: 77%